| Name | Nuformix |
|---|---|
| Epic | NFX |
| Isin | GB00BYW79Y38 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 0.05p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £0.71 | Debt ratio | n/a |
| Shares in issue | 819.31 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -543.34 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -0.08 | 52-week high / low | 0.04p / 0.40p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Nuformix |
|---|---|
| Address | 6th Floor, 60 Gracechurch Street, London, United Kingdom, EC3V 0HR |
| Telephone | +44 (0)1223 627222 |
| Website | https://nuformix.com/ |
| Director | Position |
|---|---|
| Dr Daniel Gooding | Executive Director |
| Mr Julian Gilbert | Non-Executive Chairman |
| Mrs Madeleine Kennedy | Independent Non-Executive Director |
| Assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 30/09/23 | 31/03/22 | 31/03/21 |
| Intangible asssets and goodwill | 4.08 | 4.15 | 4.19 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 4.08 | 4.15 | 4.19 |
| Inventory / work in progress | n/a | n/a | n/a |
| Trade and other receivables | 0.07 | 0.2 | 0.03 |
| Cash and equivalents | 0.2 | 0.46 | 1.67 |
| Other current assets and asset held for resale | 0.07 | 0.16 | 0.12 |
| Total of all assets | 4.42 | 4.98 | 6.01 |
| Liabilities £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 0.22 | 0.24 | 0.32 |
| Long term liabilities | n/a | n/a | n/a |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 0.22 | 0.24 | 0.32 |
| Net assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | 4.2 | 4.74 | 5.69 |
| Equity £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | 0.74 | 0.62 | 0.59 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -8.21 | -7.35 | -6.24 |
| Share premium account | 6.66 | 6.5 | 6.38 |
| Total equity | 4.2 | 4.74 | 5.69 |
| Income £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -0.93 | -1.27 | -1.37 |
| Pre-tax profit | -0.93 | -1.27 | -1.38 |